Drug Delivery Drugs In-Vitro In-Vivo 
Pharma Mirror
FEBRUARY 18, 2021
Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc.
Drug Discovery World
AUGUST 3, 2022
Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 3, 2023
As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. AT : The major interest we see is in the targeted delivery of therapeutic molecules.
XTalks
OCTOBER 1, 2020
Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.
Drug Discovery World
NOVEMBER 8, 2023
Antibody-based cancer therapies The second track of PEGS Europe 2023 is ‘Antibody-based cancer therapies’, which will feature a range of sessions made up of presentations, talks and posters which cover antibody drug conjugates (ADCs), intracellular, bispecific, and logic-gated antibodies, and conditionally active biologics.
Expert insights. Personalized for you.
130 
Let's personalize your content